Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
HIP1601
DRUG
3 trials
Sponsors
Hanmi Pharmaceutical Company Limited
Conditions
Erosive Gastroesophageal Reflux Disease
Healthy
Non-erosive Gastroesphageal Reflux Disease
Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations
NCT03372850
Hanmi Pharmaceutical Company Limited
Healthy
Start: 2018-02-15
End: 2018-06-15
Target: 96
Updated: 2018-01-17
Phase 3
Efficacy and Safety of HIP1601 Capsule
Completed
NCT04080726
Hanmi Pharmaceutical Company Limited
Erosive Gastroesophageal Reflux Disease
Start: 2018-10-25
End: 2019-12-03
Updated: 2020-11-30
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
Completed
NCT04325620
Hanmi Pharmaceutical Company Limited
Non-erosive Gastroesphageal Reflux Disease
Start: 2019-06-10
End: 2020-08-03
Updated: 2022-11-09
Related Papers
Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
2023-12-18
2 citations